Skip to main content

Table 2 Safety and efficacy variables of the study presented as mean and difference in means (95% confidence interval)

From: APCAP - activated protein C in acute pancreatitis: a double-blind randomized human pilot trial

 

N

APC

 

Placebo

Difference in means between the study groups (95% CI)

Delta SOFA score

16

1.8 (4.3)

16

-0.6 (4.1)

2.3 (-0.7 to 5.2)

Delta-non-hepatic SOFA

16

1.9 (4.1)

16

-0.2 (3.9)

2.1 (-0.8 to 4.9)

Ventilator free days

16

10.4 (9.4)

16

10.4 (11.5)

0 (-7.4 to 7.4)

Renal replacement therapy-free days

16

52.7 (12.7)

16

55.3 (9.3)

-2.6 (-10.5 to 5.3)

Vasopressor-free days

16

52.8 (7.1)

16

55.1 (6.0)

-2.6 (-5.9 to 2.3)

Alive outside hospital - days

16

17.1 (32.5)

16

34.4 (13.0)

-17.4 (-0.1 to -34.9)

Delta modified CT score

11

0.5 (2.0)

11

0.5 (1.8)

0 (-1.6 to 1.6)

Delta serum bilirubin, total (μmol/L)

16

18 (46.4)

16

-10 (17.0)

28 (3.6 to 53.1) *

Delta serum bilirubin, conjugated (μmol/L)

13

14 (31.9)

12

-11 (11.1)

25 (5.6 to 44.4) *

Delta serum creatinine (μmol/L)

16

-37 (84)

16

13 (86)

-50 (-110 to 10)

Delta platelet count (× 109/L)

16

32 (52)

16

35 (55)

-3 (-40 to 34)

Delta plasma hemoglobin mg/L

13

-226 (499.5)

16

-65 (83.2)

-161 (-413 to 92.0)

Delta serum pre-albumin mg/L

13

-50 (49.7)

12

-69 (55.2)

19 (-23.0 to 61.0)

  1. Organ-dysfunction-free days calculated for 60 days.
  2. *significant differences; CI, confidence interval.